A group of scientists at Shanghai Virogin Biotech Co. and Zhujiang Hospital in China designed a new mRNA vaccine that could prevent tumor formation associated with human papillomavirus 16 (HPV16) and also reduce its size if used as a treatment.

Using its proprietary AI-Immunology platform, Evaxion has identified novel vaccine targets against a bacterial pathogen causing severe health issues.

A vaccine based on messenger RNA (mRNA) technology against four surface proteins of the envelope and the inner membrane of the mpox virus (MPXV) demonstrated its efficacy in two animal models. Biontech SE scientists designed and tested two different combinations of antigens in mice and macaques for the two infective forms of the virus. One of them showed better results for its evaluation in clinical trials preventing the disease.

Vaxess Technologies Inc. seeks patent protection for devices that enable the reliable application of silk fibroin-based microneedle medicament patches used for delivering small molecule drugs, vaccines, peptides, biologics, antibodies, hormones or other materials into or through the skin.

The Nobel Prize-winning modification that prevents the innate immune system from recognizing injected mRNA as foreign and blocking transcription of the protein it encodes has been found on some occasions to cause ribosomal frameshifting.

The Nobel Prize-winning modification that prevents the innate immune system from recognizing injected mRNA as foreign and blocking transcription of the protein it encodes has been found on some occasions to cause ribosomal frameshifting.

Among all human papillomavirus (HPV) types described so far, the two most abundant – HPV16 and HPV18 – are responsible for 71% of all cervical cancers. The vaccines currently used are effective in preventing viral infection, but have no effect on already infected or maligned cells.

An experimental vaccine that contained antigens of both lytic and latent phases of Epstein-Barr virus (EBV), and induced both an antibody and a T cells response, was able to generate broad and long-lasting immunity against EBV in mouse models of infection. Researchers from the QIMR Berghofer Medical Research Institute and Elicio Therapeutics Inc. reported those results online in Nature Communications on Aug. 8, 2023.

For some viruses, the challenge to developing a vaccine is their rapid mutation rate. This is the major challenge to developing an HIV vaccine or a universal flu vaccine. EBV is different. Its superpower is its ability to hide.

Although huge strides have been made with antiretroviral therapy (ART) and prevention since HIV was first reported 42 years ago, there is still not an effective preventive vaccine or a scalable cure for those living with HIV. But broadly neutralizing antibodies (bNAbs) look to be a further step down the pathway to a cure, speakers said during the International AIDS Society meeting held July 23 to 26 in Brisbane, Australia.